Keyphrases
Patient-reported Outcomes
100%
Actinic Keratosis
100%
Treatment Adherence
100%
Field Treatment
100%
Ingenol Mebutate
60%
Health-related Quality of Life
60%
Treatment Satisfaction
60%
Topical Treatment
40%
Routine Clinical Practice
40%
Sweden
40%
Diclofenac
40%
Denmark
40%
Short-term Treatment
20%
Improved Health
20%
Instrument Validation
20%
Physician Questionnaire
20%
Satisfaction with Treatment
20%
Real-world Clinical Practice
20%
Randomized Clinical Trial
20%
Patient Health Questionnaire
20%
Non-adherence
20%
EQ-5D-5L
20%
Adult Patients
20%
Treatment Duration
20%
Non-persistence
20%
EQ-VAS
20%
Clinical Efficacy
20%
Treatment Efficacy
20%
Medicine and Dentistry
Patient Compliance
100%
Actinic Keratosis
100%
Patient-Reported Outcome
100%
Quality of Life
75%
Diclofenac
75%
Ingenol Mebutate
75%
Topical Treatment
50%
Dermatology
25%
Randomized Clinical Trial
25%
Treatment Duration
25%
Combination Therapy
25%
Nursing and Health Professions
Patient Compliance
100%
Patient-Reported Outcome
100%
Actinic Keratosis
100%
Diclofenac
75%
Clinical Practice
75%
Quality of Life
75%
Topical Treatment
50%
Treatment Duration
25%
Combination Therapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Diclofenac
100%
Actinic Keratosis
100%
Ingenol Mebutate
100%
Imiquimod
66%
Combination Therapy
33%
Randomized Clinical Trial
33%